2012
DOI: 10.1007/s10875-012-9716-x
|View full text |Cite
|
Sign up to set email alerts
|

Etanercept Downregulates the Th17 Pathway and Decreases the IL-17+/IL-10+ Cell Ratio in Patients with Psoriasis Vulgaris

Abstract: Our results confirmed the role of Th17 cells in the pathogenesis of psoriasis. Etanercept, but not acitretin, was able to downregulate the Th17 pathway and to increase the percentages of IL-10-producing cells in the skin.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
20
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 27 publications
(20 citation statements)
references
References 39 publications
0
20
0
Order By: Relevance
“…In another remitting patient LL37-specific T cells lost IL-17-secretion capacity. Noteworthy, the two improving patients received Etanercept, a TNF-a blocker reported to inhibit IL-17 and increase IL-10 production by T cells 46,47 . Emergence of IL-10 plus vanishing of IFN-g/Th17 responses in patients that lowered PASI is consistent with the correlation that we found between presence of LL37-specific T cells producing IFN-g, IL-17, IL-21, IL-22 (refs 7-9), (but not Tregs/Th2-cytokines IL-10/IL-4) with moderateto-severe psoriasis.…”
Section: Discussionmentioning
confidence: 99%
“…In another remitting patient LL37-specific T cells lost IL-17-secretion capacity. Noteworthy, the two improving patients received Etanercept, a TNF-a blocker reported to inhibit IL-17 and increase IL-10 production by T cells 46,47 . Emergence of IL-10 plus vanishing of IFN-g/Th17 responses in patients that lowered PASI is consistent with the correlation that we found between presence of LL37-specific T cells producing IFN-g, IL-17, IL-21, IL-22 (refs 7-9), (but not Tregs/Th2-cytokines IL-10/IL-4) with moderateto-severe psoriasis.…”
Section: Discussionmentioning
confidence: 99%
“…The ability of TNFα to promote pulmonary IL-17A expression after O 3 exposure is consistent with the role of TNFα in other pathogenic states. For example, etanercept reduces the elevated blood and skin Th17 cells observed in patients with psoriasis [26]. Similarly, another anti-TNFα therapy, infliximab, reduces IL-17A in ocular fluid from uveitis patients with Behcet’s disease [27].…”
Section: Discussionmentioning
confidence: 99%
“…Instead, TNFα recruits neutrophils in part by inducing expression of other cytokines and chemokines [24], [25]. In several pathological states, TNFα induces the expression of IL-17A [26], [27]. Hence, we hypothesized that TNFα contributes to neutrophil recruitment following subacute O 3 exposure by promoting recruitment to or activation of IL-17A + γδ T cells in the lungs.…”
Section: Introductionmentioning
confidence: 99%
“…The use of etanercept, a competitive inhibitor of TNF‐α, for the treatment of HS was less encouraging and showed only minimal and inconsistent efficacy . However, in patients with psoriasis, etanercept downregulated the Th17 pathway and improved psoriasis‐associated depression …”
Section: Therapeutic Agents Affect the T Helper 17 Cell/regulatory T‐mentioning
confidence: 99%